We report on nine patients (eight cases of MS and one case of NMOSD) who presented a disease relapse in close temporal association with their first AZD1222 vaccination dose against COVID-19. These patients had been stable for a median period of six years, with no evidence of disease activity and no change in their medication. After a median of 13 days (7 to 25 days) from vaccination, they developed a new relapse with increased disability and new lesions on magnetic resonance imaging. Although this association may be rare, it might be an adverse event of AZD1222.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511887 | PMC |
| http://dx.doi.org/10.1016/j.msard.2021.103321 | DOI Listing |
Publication Analysis
Top Keywords
adverse event
8
azd1222 vaccination
8
relapse multiple
4
multiple sclerosis
4
sclerosis neuromyelitis
4
neuromyelitis optica
4
optica potential
4
potential adverse
4
event astrazeneca
4
astrazeneca azd1222
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!